Table 1. Anthropometric data of the study population and relevant medications in CKD patients.
| Patients (36m / 20f) | Controls (28m / 32f) | |
|---|---|---|
| Age [y] | 12.0 (4.00–18.0) | 13.5 (7.00–18.0) |
| absolute BMI [kg/m2] | 18.6 (9.25–35.9) | 19.8 (15.0–28.1) |
| standardized BMI [SDS] | 0.12 (-7.47–3.14) | 0.19 (-1.32–1.92) |
| eGFR [ml/min/1.73m2] | 117 (22.8–200) | |
| Duration of disease [y] | 6.92 (0.17–16.7) | |
| Antihypertensive Drugs (yes / no) | 36/20 | |
| ACE-Inhibitors | 22 | |
| AT1 receptor antagonists | 14 | |
| Beta blockers | 13 | |
| Alpha blockers | 3 | |
| Vasodilators | 10 | |
| Diuretics | 15 | |
| Immunosuppressive therapy (yes / no) | 20/36 | |
| Corticosteroids | 11 | |
| Calcineurin-Inhibitors | 14 | |
| Everolimus | 1 | |
| Mycophenolate mofetil | 14 | |
| Statins | 5 | |
| Erythropoietin | 7 | |
| Growth Hormone | 1 | |
| 25-Hydroxyvitamin D / Calcitriol | 25 |